HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Prognostic factors for cure, recurrence and long-term survival after surgical resection of thymoma.

AbstractINTRODUCTION:
To determine long-term outcome and risk factors for recurrence after thymectomy.
METHODS:
Patients who underwent thymectomy (n = 262) for a thymic tumor (1986-2010) were identified from a prospective database. Patients were classified according to World Helath Organization (WHO) histologic classification, Masaoka staging system, and completeness of resection. Risk factors for recurrence: WHO histology, tumor size, Masaoka stage and completeness of resection were analyzed.
RESULTS:
Of 262 patients, 51% were female, median age was 55 years, and 39% had myasthenia gravis. Median follow-up was 7.5 years, median tumor size was 5.4 cm, and Masaoka stage distribution was: I (25%), II (47%), III (17%), IV (4%), and (7%) not classified. Of 200 patients classified under the WHO system, there were (7%) type A, (22%) type AB, and (71%) type B; 83% had complete resection. One-hundred and sixty-nine patients received adjuvant radiotherapy, eight adjuvant chemoradiotherapy and 14 neoadjuvant chemoradiotherapy. Overall survival was 95% at 5 years, 91% at 10 years and 91% at 15 years. Recurrence occurred in 12 patients and disease-related death in four patients. Five patients underwent re-resection for recurrence with survival of 2-15 years. Only Masaoka stage and tumor size were associated with statistically significant risk of recurrence on multivariate analysis.
CONCLUSION:
Resectable thymoma is associated with excellent prognosis. Aggressive resection of recurrent disease yielded excellent long-term results. Higher Masaoka stage is associated with a greater chance of incomplete resection. Higher Masaoka stage and increasing tumor size are independent factors associated with recurrence.
AuthorsNajib Safieddine, Geoffrey Liu, Kris Cuningham, Tsao Ming, David Hwang, Anthony Brade, Andrea Bezjak, Stefan Fischer, Wei Xu, Sassan Azad, Marcelo Cypel, Gail Darling, Kazu Yasufuku, Andrew Pierre, Marc de Perrot, Tom Waddell, Shaf Keshavjee
JournalJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (J Thorac Oncol) Vol. 9 Issue 7 Pg. 1018-1022 (Jul 2014) ISSN: 1556-1380 [Electronic] United States
PMID24926546 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Topics
  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Chemoradiotherapy, Adjuvant
  • Female
  • Follow-Up Studies
  • Humans
  • Male
  • Middle Aged
  • Neoadjuvant Therapy
  • Neoplasm Recurrence, Local (surgery)
  • Neoplasm Staging
  • Prognosis
  • Radiotherapy, Adjuvant
  • Risk Factors
  • Survival Rate
  • Thymectomy
  • Thymoma (classification, pathology, therapy)
  • Thymus Neoplasms (classification, pathology, therapy)
  • Tumor Burden
  • World Health Organization
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: